COVID-19 is a call to service: Kingston is responding
This blogpost was co-written by Jane Philpott, David Pichora, Cathy Szabo, and Kieran Moore
Related Articles
Is Evidence-based Medicine being hijacked in oncology?
My talk delivered to Consilium Scientific on August 26th, 2021#oncology #evidence-based medicine #surrogate #endpoints #crossover #RCT
Is Evidence-based Medicine being hijacked in oncology?
My talk delivered to Consilium Scientific on August 26th, 2021#oncology #evidence-based medicine #surrogate #endpoints #crossover #RCT
Early Phase Clinical Trials in LMICs: necessity or superfluous?
A talk delivered at the “Early Phase Clinical Trials & Global Oncology: a new deal?” symposium in Marseille, France in June 2021 virtually. #globaloncology #…
Early Phase Clinical Trials in LMICs: necessity or superfluous?
A talk delivered at the “Early Phase Clinical Trials & Global Oncology: a new deal?” symposium in Marseille, France in June 2021 virtually. #globaloncology #…
What patients and advocates should know about cancer clinical trials?
Not all clinical trials are designed the same. Patients should choose well-designed patient-centric clinical trials for participation. #cancer #clinicaltrial…
Understanding Cancer Clinical Trials from a Patient/Advocate Perspective
Talk was given to participants of ColonCon in Kingston in February 2020.
Surrogate Endpoints in Oncology and their role in regulatory approval
This is a webinar delivered to patient advocates on June 25, 2020 organized by the National Breast Cancer Coalition. Link to the article discussed on…
Cancer treatment at the end of life
Interview for ecancer based on my paper on cancer treatment in the last 6 months of life. Paper can be downloaded for free here: https://ecancer.org/en/journ…
Surrogate Endpoints in Oncology and their role in regulatory approval
This is a webinar delivered to patient advocates on June 25, 2020 organized by the National Breast Cancer Coalition. Link to the article discussed on…